Sunday 28 April 2024
Internal Reference Number: FOI_7487
Date Request Received: 11/10/2023 00:00:00
Date Request Replied To: 24/10/2023 00:00:00
This response was sent via: By Email
Request Summary: new biologic and targeted medications within dermatology and respiratory medicine
Request Category: Companies
| Question Number 1: How many patients were treated in September 2023 (or latest available month) by the Dermatology department with the following drugs: • Abrocitinib (Cibinqo) • Baricitinib (Olumiant) • Dupilumab (Dupixent) • Omalizumab (Xolair) • Tralokinumab (Adtralza) • Upadacitinib (Rinvoq) | |
| Answer To Question 1: • Abrocitinib (Cibinqo) 0 • Baricitinib (Olumiant) 0 • Dupilumab (Dupixent) 17 • Omalizumab (Xolair) 5 • Tralokinumab (Adtralza) 0 • Upadacitinib (Rinvoq) <5 | |
| Question Number 2: How many patients were treated in September 2023 (or latest available month) by the Respiratory Medicine department with the following drugs: • Benralizumab (Fasenra) • Dupilumab (Dupixent) • Mepolizumab (Nucala) • Omalizumab (Xolair) • Reslizumab (Cinqaero) • Tezepelumab (Tezspire) | |
| Answer To Question 2: Benralizumab (Fasenra) <5 • Dupilumab (Dupixent) <5 • Mepolizumab (Nucala) <5 • Omalizumab (Xolair) - 6 patients received this medication. • Reslizumab (Cinqaero) <5 • Tezepelumab (Tezspire) <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
